Browsing by Author "Rocha, Nuno Barbosa"
Now showing 1 - 6 of 6
Results Per Page
Sort Options
- Assessing the management of excessive daytime sleepiness by napping benefitsPublication . Murillo-Rodríguez, Eric; Yamamoto, Tetsuya; Monteiro, Diogo; Budde, Henning; Rocha, Nuno Barbosa; Cid, Luis; Teixeira, Diogo S.; Telles-Correia, Diogo; Veras, André Barciela; Machado, Sérgio; Imperatori, Claudio; Torterolo, PabloPurpose Demanding lifestyle characterized by extended working hours, shift work schedules as well as excessive use of mobile gadgets leads to the disruption of the circadian and homeostatic factors affecting the sleep quality of individuals. As consequence, subjects complain of suffering several sleep disorders some of them characterized by inducing excessive daytime sleepiness (EDS). Currently, the therapeutic approaches for managing EDS include medication, promotion of sleep hygiene, cognitive and behavioral therapy or using of continuous positive airway pressure machine. In this review, we propose the posology of the personalized sleep medicine by the prescription of naps for treating EDS. Methods This review included the online search in PubMed and manual review of articles (basic and clinical trials) of a range of personalized medicine potentially associated to factors of dosage in areas such as nutrition, sports and sleep. Articles in English were identified and subsequently analyzed for consideration for this review. Results Current evidence has demonstrated that naps exert positive outcomes for individuals complaining with EDS. The dosage of naps might follow similar procedures as reported for personalized interventions in diets or exercise programs (by taking the right dose, at the proper time, with a recommended frequency) which have demonstrated successfully results. Conclusions The management of EDS may include the personalized sleep medicine considering the prescription of dosage of naps.
- Blueberry intake included in hypocaloric diet decreases weight, glucose, cholesterol, triglycerides and adenosine levels in obese subjectsPublication . Higuera-Hernández, María Fernanda; Reyes-Cuapio, Elena; Gutiérrez-Mendoza, Marissa; Budde, Henning; Blanco-Centurión, Carlos; Veras, André Barciela; Rocha, Nuno Barbosa; Yamamoto, Tetsuya; Monteiro, Diogo; Zaldívar-Rae, Jaime; Aldana-Aranda, Dalila; Machado, Sérgio; Murillo-Rodríguez, EricObesity is a disease characterized by an excessive accumulation of fat in the body and it has been linked the enhancement of inflammation-related endogenous molecules, such as adenosine (AD). Since blueberries may induce anti-obesity effects, we tested the hypothesis that blueberries consumption contained in hypocaloric diet would decrease weight, BMI as well as glucose, cholesterol, triglycerides and AD levels in obese subjects. The baseline conditions of obesity-related variables were collected for all subjects prior the implementation of blueberries intake. Later, participants received a hypocaloric diet that included the consumption of blueberries (50 g/day) during 30 days. We found that male obese subjects that consumed blueberries showed a decrease in weight, glucose, cholesterol, triglycerides and AD whereas female obese subjects that ate blueberries in hypocaloric diet showed no differences in weight, BMI, glucose and triglycerides but displayed a diminution in cholesterol and AD levels. Data suggest that intake of blueberries seems to decrease some of the obese-linked parameters in male or female subjects. Importantly, blueberry consumption decreased the inflammation-related compound AD in both sexes
- Sleep and Neurochemical Modulation by DZNep and GSK-J1: Potential Link With Histone Methylation StatusPublication . Murillo-Rodríguez, Eric; Arankowsky-Sandoval, Gloria; Barros, Jorge Aparecido; Rocha, Nuno Barbosa; Yamamoto, Tetsuya; Machado, Sérgio; Budde, Henning; Telles-Correia, Diogo; Monteiro, Diogo; Cid, Luis; Veras, André BarcielaHistone methylation/demethylation plays an important modulatory role in chromatin restructuring, RNA transcription and is essential for controlling a plethora of biological processes. Due to many human diseases have been related to histone methylation/demethylation, several compounds such as 3-deazaneplanocin A (DZNep) or 3-((6-(4,5-Dihydro-1H-benzo[d]azepin-3(2H)-yl)-2-(pyridin-2-yl)pyrimidin-4-yl)amino)propanoic acid; N-[2-(2-pyridinyl)-6-(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)-4-pyrimidinyl]-β-Alanine (GSK-J1), have been designed to inhibit histone methylase or suppress histone demethylase, respectively. In the present study, we investigated the effects on the sleep-wake cycle and sleep-related neurochemical levels after systemic injections of DZNep or GSK-J1 given during the light or dark phase in rats. DZNep dose-dependently (0.1, 1.0, or 10 mg/kg, i.p.) prolonged wakefulness (W) duration while decreased slow wave sleep (SWS) and rapid eye movement sleep (REMS) time spent during the lights-on period with no changes observed in dark phase. In opposite direction, GSK-J1 (0.1, 1.0, or 10 mg/kg, i.p.) injected at the beginning of the lights-on period induced no statistical changes in W, SWS, or REMS whereas if administered at darkness, we found a diminution in W and an enhancement in SWS and REMS. Finally, brain microdialysis experiments in freely moving animals were used to evaluate the effects of DZNep or GSK-J1 treatments on contents of sleep-related neurochemicals. The results showed that DZNep boosted extracellular levels of dopamine, norepinephrine, epinephrine, serotonin, adenosine, and acetylcholine if injected at the beginning of the lights-on period whereas GSK-J1 exerted similar outcomes but when administered at darkness. In summary, DZNep and GSK-J1 may control the sleep-wake cycle and sleep-related neurochemicals through histone methylation/demethylation activity.
- Sleep Disorders and GenesPublication . Murillo-Rodríguez, Eric; Yamamoto, Tetsuya; Veras, André Barciela; Rocha, Nuno Barbosa; Telles-Correia, Diogo; Budde, Henning; Machado, Sérgio; Monteiro, Diogo; Torterolo, PabloThe sleep-wake cycle is a neurobiological phenomenon that shows intervals of activity alternating with restfulness that appears with a periodicity approximating the 24h day-night cycle. The sleep-wake cycle is under the control of diverse neuroanatomical and neurochemical systems, including monoaminergic, cholinergic, adenosinergic among many other systems. In addition, neuroanatomical centers linked to sleep promotion, such as hypothalamus, project to the cerebral cortex, subcortical relays and brainstem. In addition, the sleep-wake cycle has been associated to aberrant features known as sleep disorders. Here, we will discuss the role of specific gene expression on sleep disturbances. Given the expansion of the knowledge in the sleep-wake cycle area, it is indeed ambitious to describe all the genetics involved in the sleep modulation. However, in this chapter we reviewed the current understanding of the sleep disorders and gene expression.
- The Endocannabinoid System May Modulate Sleep Disorders In AgingPublication . Murillo-Rodríguez, Eric; Budde, Henning; Veras, André Barciela; Rocha, Nuno Barbosa; Telles-Correia, Diogo; Monteiro, Diogo; Cid, Luis; Yamamoto, Tetsuya; Machado, Sérgio; Torterolo, PabloAging is an inevitable process that involves changes along life in multiple neurochemical, neuroanatomical, hormonal systems, and many others. In addition, these biological modifications lead to an increase in age-related sickness such as cardiovascular diseases, osteoporosis, neurodegenerative disorders, and sleep disturbances, among others that affect activities of daily life. Demographic projections have demonstrated that aging will increase its worldwide rate in the coming years. The research on chronic diseases of the elderly is important to gain insights into this growing global burden. Novel therapeutic approaches aimed for treatment of age-related pathologies have included the endocannabinoid system as an effective tools since this biological system shows beneficial effects in preclinical models. However, and despite these advances, little has been addressed in the arena of the endocannabinoid system as option for treating sleep disorders in aging since experimental evidence suggests that some elements of the endocannabinoid system modulate the sleep-wake cycle. This article addresses this less-studied field, focusing on the likely perspective of the implication of the endocannabinoid system in the regulation of sleep problems reported in aged. We conclude that beneficial effects regarding the putative efficacy of the endocannabinoid system as therapeutic tools in aging is either inconclusive or still missing.
- The retinoid X receptor: a nuclear receptor that modulates the sleep-wake cycle in ratsPublication . Murillo-Rodríguez, Eric; Millán-Aldaco, Diana; Arankowsky-Sandoval, Gloria; Yamamoto, Tetsuya; Cid, Luis; Monteiro, Diogo; Rocha, Nuno Barbosa; Telles-Correia, Diogo; Teixeira, Diogo S.; Veras, André Barciela; Budde, Henning; Machado, Sérgio; Imperatori, Claudio; Torterolo, PabloRationale The nuclear receptor retinoid X receptor (RXR) belongs to a nuclear receptor superfamily that modulates diverse functions via homodimerization with itself or several other nuclear receptors, including PPARα. While the activation of PPARα by natural or synthetic agonists regulates the sleep-wake cycle, the role of RXR in the sleep modulation is unknown. Objectives We investigated the effects of bexarotene (Bexa, a RXR agonist) or UVI 3003 (UVI, a RXR antagonist) on sleep, sleep homeostasis, levels of neurochemical related to sleep modulation, and c-Fos and NeuN expression. Methods The sleep-wake cycle and sleep homeostasis were analyzed after application of Bexa or UVI. Moreover, we also evaluated whether Bexa or UVI could induce effects on dopamine, serotonin, norepinephrine epinephrine, adenosine, and acetylcholine contents, collected from either the nucleus accumbens or basal forebrain. In addition, c-Fos and NeuN expression in the hypothalamus was determined after Bexa or UVI treatments. Results Systemic application of Bexa (1 mM, i.p.) attenuated slow-wave sleep and rapid eye movement sleep. In addition, Bexa increased the levels of dopamine, serotonin, norepinephrine epinephrine, adenosine, and acetylcholine sampled from either the nucleus accumbens or basal forebrain. Moreover, Bexa blocked the sleep rebound period after total sleep deprivation, increased in the hypothalamus the expression of c-Fos, and decreased NeuN activity. Remarkably, UVI 3003 (1 mM, i.p.) induced opposite effects in sleep, sleep homeostasis, neurochemicals levels, and c-Fos and NeuN activity. Conclusions The administration of RXR agonist or antagonist significantly impaired the sleep-wake cycle and exerted effects on the levels of neurochemicals related to sleep modulation. Moreover, Bexa or UVI administration significantly affected c-Fos and NeuN expression in the hypothalamus. Our findings highlight the neurobiological role of RXR on sleep modulation.